Neoadjuvant chemoradiotherapy for oesophageal cancer: Still looking for a challenger to the CROSS regimen

Randomised studies are so rare in the setting of neoadjuvant chemoradiotherapy (nCRT) for oesophageal cancer that Mukherjee et al. [1] have to be commended for conducting the NEOSCOPE study, which evaluated induction chemotherapy followed by carboplatin/paclitaxel nCRT (nCarPacRT) versus induction chemotherapy followed by oxaliplatin/capecitabine nCRT. This is also the first randomised study in the field that routinely uses an image-guided radiotherapy supported by a peer-reviewed real-time radiation therapy (RT) quality assurance.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tkv5C9
via IFTTT